CCR2 and CX3CR1 steer immune cells in lung tuberculosis

Tuberculosis remains the deadliest infectious disease worldwide, driven by Mycobacterium tuberculosis (Mtb), a respiratory pathogen that survives inside the very immune cells meant to destroy it. In people who are susceptible, phagocytes — immune cells that engulf microbes — often fail to eliminate Mtb, allowing the bacterium to persist. A key reason for persistence is that recruited monocyte-derived cells in the lung can become long-lived reservoirs for infection instead of effective killers. To better understand how these cells arrive and behave where they matter most, researchers led by J. Ernst investigated two chemokine receptors found on monocyte-derived cells, CCR2 and CX3CR1. These receptors help control how immune cells move through the body. The team set out to tease apart the specific duties of CCR2 and CX3CR1 during pulmonary tuberculosis, focusing on how monocytes reach the infected lung and how monocyte-derived cells are positioned in nearby lymph nodes. By clarifying these trafficking steps, the study aims to explain why recruited phagocytes accumulate in places that allow Mtb to persist and to point toward host-directed strategies that could work with antibiotics to clear infection more effectively.

The study focused on monocyte-derived cells that express the chemokine receptors CCR2 and CX3CR1 and examined their behavior in the infected lung and the mediastinal lymph node. The researchers report that CCR2 functions primarily to recruit monocytes into the lung, bringing fresh immune cells into the site of infection. In contrast, CX3CR1 does not appear to be the main recruiter to the lung but instead modulates where monocyte-derived CD11c pos cells sit inside the mediastinal lymph node. Importantly, interfering with CX3CR1 signaling also worsened Mtb control in the mediastinal lymph node, which helps explain why CX3CR1 expression persists on these cells during pulmonary tuberculosis. These results separate the roles of CCR2 and CX3CR1: CCR2 brings monocytes to the infected lung, while CX3CR1 helps position monocyte-derived cells once they reach the lymph node, with consequences for local bacterial control.

These findings shed light on a basic feature of the host response to tuberculosis and other lung infections: the locations and movements of monocyte-derived cells matter for whether they serve as protective effectors or as niches for persistent bacteria. By showing that CCR2 and CX3CR1 have distinct roles — recruitment versus positioning — the work suggests new points of intervention. Therapies that modify recruitment signals or reposition monocyte-derived cells could change whether these cells clear bacteria or allow them to persist. In practical terms, combining such host-directed approaches with existing antimicrobials could reduce the reservoirs of persistent Mtb in lung tissue and mediastinal lymph nodes, potentially leading to faster, more durable cures. The study provides a rationale for further research into targeting chemokine pathways as an adjunct to antibiotic treatment in pulmonary tuberculosis.